Financings

Deciphera Pharmaceuticals Inc. priced its registered underwritten public offering for expected gross proceeds of $400 million.

Landos Biopharma Inc. completed a $60 million series B financing.

Portola Pharmaceuticals Inc. plans an underwritten public offering of $200 million of its common stock and expects to grant underwriters a 30-day option to purchase up to $30 million in additional shares to fill overallotments.

Deals

Alnylam Pharmaceuticals Inc. and Ironwood Pharmaceuticals Inc. have inked a U.S. gastrointestinal disease education and promotional agreement for Alnylam's givosiran, an RNAi therapeutic candidate targeting aminolevulinic acid synthase 1 to treat acute hepatic porphyria.

Asklepios Biopharmaceutical Inc. said it acquired Synpromics Ltd., which will operate as a wholly owned subsidiary and remain in Edinburgh, U.K..

Curevac AG signed a collaborative research agreement with Yale University covering discovery research on an undisclosed number of mRNA-based candidates for pulmonary diseases.

Genecentric Therapeutics Inc. has acquired Immunogenomics LLC, a provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.

Harvard University and Merck & Co. Inc. are launching a collaboration for up to four years to support immuno-oncology research.

Integrated Biotherapeutics Inc. is collaborating with the Institute for Bioscience and Biotechnology Research on a new approach to bacterial disease.

Neoleukin Therapeutics Inc. completed its merger with Aquinox Pharmaceuticals Inc. The combined entities will be known as Neoleukin and trade under the new ticker symbol NLTX on Nasdaq.

Oncologie Inc. established a clinical collaboration with Merck & Co. Inc. to evaluate a combination of its vascular targeting agent, bavituximab, a beta 2 glycoprotein 1 inhibitor, with the anti-PD-1 therapy Keytruda (pembrolizumab) in advanced gastric or gastroesophageal cancer.

Phio Pharmaceuticals Corp. entered a research collaboration with the Helmholtz Zentrum München that covers the design and development of new targets based on the company's self-delivering RNAi platform for use in cancer immunotherapies.

Ultragenyx Pharmaceutical Inc. has agreed to pay $20 million for an exclusive option to acquire Genetx Biotherapeutics LLC, the developer of a University of Texas-sourced antisense oligonucleotide for the potential treatment of Angelman syndrome.

...And more

An African trial testing four Ebola drugs was stopped early for favorable results, finding two of the therapies, Regeneron Pharmaceuticals Inc.'s REGN-EB3 and the NIH-developed MAb-114, gave Ebola-infected participants a greater chance of survival than either Gilead Sciences Inc.'s remdesivir or Zmapp (Mapp Biopharmaceutical Inc., Defryus Inc.), considered the standard of care.

Biotime Inc. said it rebranded as Lineage Cell Therapeutics Inc. to better reflect its cell therapy platform.

Deciphera Pharmaceuticals Inc.'s shares spiked last week as results of a pivotal phase III study showed its lead candidate, ripretinib, enabled people with fourth-line and beyond gastrointestinal stromal tumors to live a median of 6.3 months before disease progression vs. one month with a placebo.

Harmony Biosciences LLC received U.S. clearance for Wakix (pitolisant) for the treatment of excessive daytime sleepiness in adults with the chronic sleep disorder.

The Institute for Clinical and Economic Review said it plans to assess the comparative clinical effectiveness and value of Novartis AG's crizanlizumab and Global Blood Therapeutics Inc.'s voxelotor for the treatment of sickle cell disease.

Kala Pharmaceuticals Inc. said it would look to data from a third phase III trial of its dry eye disease candidate, KPI-121 0.25%, to satisfy the request, in an FDA complete response letter, for efficacy data from an additional trial to support its NDA.

Passage Bio Inc. launched a natural history study to evaluate patients with type 1 and type 2 GM1 gangliosidosis that will be run by the Orphan Disease Center in the Perelman School of Medicine at the University of Pennsylvania.

Roche Holding AG's Genentech unit received FDA approval for Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small-cell lung cancer, and also gained accelerated approval to the tyrosine kinase inhibitor for adult and pediatric patients (12 and older) with solid tumors that have a NTRK gene fusion.

The FDA cleared oral pretomanid, developed by the TB Alliance, under the Limited Population Pathway for Antibacterial and Antifungal Drugs as part of a three-drug, six-month, all-oral regimen for the treatment of tuberculosis in people with extensively drug-resistant disease or multidrug-resistant TB who are treatment-intolerant or non-responsive.

Theratechnologies Inc. has regained complete control over distribution rights of Egrifta (tesamorelin) worldwide, following the termination of agreements with commercial partners in various territories outside of the U.S. and Canada.

The U.S. District Court of New Jersey ruled that patents for Sandoz Inc.'s biosimilar, Erelzi (etanercept-szzs), a potential competitor to Amgen Inc.'s arthritis treatment Enbrel (etanercept), should never have been granted. Sandoz, the generics division of Novartis AG, plans to appeal the court ruling.

The largest-ever genomics study of Clostridium difficile has found an emerging new species of the bacterium is selected to thrive on a Western sugar-rich diet and to produce high levels of resistant spores, adapting it to maximize transmission in hospitals and other health care facilities.

No Comments